• Neomorph

  Participated · Series B · Apr 2026

  Neomorph develops molecular glue degraders and has built a proprietary platform to engineer neomorphic protein surfaces that enable targeted protein degradation of disease drivers previously considered undruggable. Its lead investigational candidate, NEO‑811, is designed to induce degradation of ARNT (HIF‑1β) and is being evaluated in a first‑in‑human Phase 1/2 open‑label monotherapy trial in patients with locally advanced or metastatic non‑resectable clear cell renal cell carcinoma. The company says its platform spans multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases, creating what it calls the world’s largest proprietary molecular glue target space. Neomorph has partnerships with pharmaceutical companies including Novo Nordisk, Biogen, and AbbVie across cardiometabolic disease, rare disease, neurology, oncology, and immunology. The company plans to use the $100 million Series B to advance NEO‑811 through clinical development and to progress its broader pipeline across multiple therapeutic areas. Neomorph was founded in 2020 and is headquartered in San Diego.

• Precede Biosciences

  Participated · Series B · Jan 2026

  Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

• Predicta Biosciences

  Participated · Series A · Oct 2025

  Predicta Biosciences builds laboratory-developed tests that combine deep genomic and immune profiling to improve the diagnosis and management of blood cancers such as multiple myeloma. Its first product, GenoPredicta, launched in April and can be run on either peripheral blood or bone marrow to help physicians identify molecular drivers of disease and predict patient response to immunotherapies like CAR-T cells and bispecific antibodies. The company operates a CLIA-approved laboratory and plans to use new capital to expand both its team and lab infrastructure. Beyond diagnostics, Predicta intends to leverage its growing dataset to discover and commercialize precision therapeutics. The firm collaborates with clinical providers and advocacy groups, including the HealthTree Foundation, to accelerate adoption. Brian McKernan, a three-time biotech founder and former CEO of Fluent BioSciences, has been appointed CEO to steer commercialization and future product development. Financial metrics such as revenue or user numbers were not disclosed in the article.

• NextPoint Therapeutics

  Participated · Series B · Feb 2024

  NextPoint Therapeutics is developing a new class of precision oncology therapeutics that target the HHLA2 pathway (also known as B7-H7). The company is advancing two immuno-oncology clinical programs, NPX267 and NPX887, and is developing additional tumor-targeting therapeutic modalities that exploit HHLA2 upregulation. NextPoint integrates foundational science with a defined clinical biomarker strategy to deliver monotherapies for patients who do not benefit from PD-1/L1 inhibitors. The company positions HHLA2 as both a novel immune checkpoint and a tumor-targeting mechanism to treat both hot and cold tumors. Funds from the recent financing will be used to advance NPX267 and NPX887 and to propel development of additional therapeutic modalities in the pipeline that target the HHLA2 tumor antigen. NextPoint says it will advance a diverse set of assets into clinical trials to reshape immunotherapy into precision oncology. NextPoint Therapeutics is developing precision immuno-oncology therapies focused on the newly discovered HHLA2 pathway. Its two lead programs aim to deliver monotherapies for patients who do not benefit from PD-1/L1 inhibitors by re-activating immune cells suppressed by HHLA2-driven immune evasion. HHLA2 is described as a B7 family tumor antigen that is independent of PD-L1 and often strongly expressed in PD-L1–negative, hard-to-treat cancers. The company reports preclinical data and analyses of existing clinical datasets supporting the importance of the HHLA2 pathway as a tumor-suppressive mechanism. NextPoint originated from the academic work of founders Gordon Freeman, PhD, (Dana-Farber Cancer Institute) and XingXing Zang, PhD, (Albert Einstein College of Medicine) and is led by CEO Detlev Biniszkiewicz, PhD. The company plans to use new financing to advance its two lead precision immuno-oncology programs into the clinic.

• Kojin Therapeutics

  Participated · Series A · Jun 2021

  Kojin Therapeutics develops targeted therapeutics based on a proprietary approach to cell state and ferroptosis biology. The company has created a ferroptosis-based drug discovery platform that links non-genetic cell-state classifications to known biochemical processes to identify selective therapeutic targets. Its initial pipeline is focused on oncology, including hard-to-treat and drug-resistant cancers, with potential applications in immune-based disorders, fibrosis, and neurodegeneration. Kojin plans to use Series A proceeds to accelerate its discovery platform and advance its pipeline. The company was founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan and is led by acting CEO Amir Nashat, acting President Susan Langer, and CSO Kay Ahn. Kojin launched from Cambridge, Mass., with a $60 million Series A to commercialize its approach.

No current team members are available.